Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast)

Ehui EBOİ

doi:https://doi.org/10.5799/jmid.328859

Article Details

Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast)

Authors:

Ehui EBOİ

Publisher:

Sağlık Araştırmaları Derneği

Main Topics:

Promotion of health

Journal:

Journal of Microbiology and Infectious Diseases 2016 Vol.6 Issue 4, pp.149-155

Document Type:

Article

Publication Date:

11/2016

Document Language:

Turkish

Document ID (Org No.):

2000487527

Frequency:

Quarterly

eISSN:

2146-9369

pISSN:

2146-3158

DOI:

https://doi.org/10.5799/jmid.328859

Abstract:

 

Introduction: Atazanavir is a protease inhibitor recently introduce in the therapeutic arsenal for second-line antiretroviral
therapy in Ivory Coast. The objective of this study was to compare the efficacy and safety of a second-line treatment
with 2 NRTIs + boosted lopinavir (LPV/r) versus 2 NRTIs + boosted atazanavir (ATV/r) in HIV-1 positive patients
in Abidjan.
Patients and Methods: Retrospective, comparative, single-center study, in 194 HIV-1 positive patients (143 with LPV/r,
51 with ATV/r), failed a first-line treatment, followed in Abidjan on 1 May 2009 to 30 June 2010. The analysis focused
on clinical parameters and immuno-virological data. The principal judgement criterion was the proportion of patients
with undetectable viral load in both groups after 12 months of HAART. Tolerance was found on the frequency of adverse
events grade 3-4 during follow-up.
Results: Clinically, improvement of the general condition and regression of opportunistic infections was similar in both
groups. The average gain of CD4 after 12 months of follow-up was +357/mm3
 in the LPV/r group versus +278 mm3
 for
ATV/r group (p = 0.012). The percentage of patients with undetectable viral load was similar in both groups (92% vs.
96% ; p = 0.535). The frequency of grade 3-4 adverse events was similar in both groups.
Conclusion: HAART with LPV/r is at least as efficient as with ATV/r in second-line treatment, in terms of viral load reduction,
with better recovery of CD4. LPV/r is an excellent second-line treatment in resource-limited countries. J Microbiol
Infect Dis 2016;6(4): 149-155  Abidjan, Atazanavir, HIV, Lopinavir, Second-line, Sub-Saharan Africa.

Article Details

Boosted- lopinavir versus boosted- atazanavir plus two nucleoside reverse transcriptase inhibitors in second- line antiretroviral therapy in HIV-1 infected patients in Abidjan (Ivory Coast)

Authors: Ehui EBOİ

Publisher: Sağlık Araştırmaları Derneği

Main Topics: Promotion of health

Journal: Journal of Microbiology and Infectious Diseases 2016 Vol.6 Issue 4, pp.149-155

Document Type: Article

Publication Date: 11/2016

Document Language: Turkish

Document ID (Org No.): 2000487527

Frequency: Quarterly

eISSN: 2146-9369

pISSN: 2146-3158

DOI: https://doi.org/10.5799/jmid.328859

Issues

Authors:

Ehui EBOİ

Publisher:

Sağlık Araştırmaları Derneği

Main Topics:

Promotion of health

Journal:

Journal of Microbiology and Infectious Diseases 2016 Vol.6 Issue 4, pp.149-155

Document Type:

Article

Publication Date:

11/2016

Document Language:

Turkish

Document ID (Org No.):

2000487527

Frequency:

Quarterly

eISSN:

2146-9369

pISSN:

2146-3158

DOI:

https://doi.org/10.5799/jmid.328859